Come si colloca il rapporto HMDC.F di PS rispetto ai suoi colleghi?

HMDC.F ha un buon valore in base al suo rapporto Price-To-Sales ( 3.2 x) rispetto alla media dei peer ( 8 x).

Come si colloca il HMDC.F's PS Ratio rispetto ad altre aziende del US Pharmaceuticals settore?

HMDC.F ha un buon valore in base al suo rapporto Price-To-Sales ( 3.2 x) rispetto alla media del settore US Pharmaceuticals ( 2.9 x).

Qual è il HMDC.F PS Ratio rispetto al suo Fair PS Ratio? Si tratta del PS Ratio atteso, tenendo conto delle previsioni di crescita degli utili, dei margini di profitto e di altri fattori di rischio della società.

Dati insufficienti per calcolare il Fair Ratio di HMDC.F Price-To-Sales per l'analisi di valutazione.

Qual è il prezzo equo di HMDC.F se si considerano i suoi flussi di cassa futuri? Per questa stima utilizziamo un modello di Discounted Cash Flow.

HMDC.F ( $3.82 ) viene scambiato al di sotto della nostra stima del [[fair value]] ( $13.46 )

Qual è la previsione a 12 mesi degli analisti e abbiamo una qualche fiducia statistica nell'obiettivo di prezzo del consenso?

Dati insufficienti per mostrare la previsione dei prezzi.

HUTCHMED (China) (OTCPK:HMDC.F) - Prezzo delle azioni, notizie e analisi

HMDC.F Panoramica delle azioni

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. Maggiori dettagli

HMDC.F analisi fondamentale
Punteggio fiocco di neve
Valutazione	4/6
Crescita futura	4/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Negoziato a 71.7% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 31.13% all'anno

Analisi del rischio

Le azioni sono altamente illiquide

HUTCHMED (China) Limited Concorrenti

Wave Life Sciences

NasdaqGM:WVE

US$2.3b

Tarsus Pharmaceuticals

NasdaqGS:TARS

US$1.8b

Harmony Biosciences Holdings

NasdaqGM:HRMY

US$2.0b

Amphastar Pharmaceuticals

NasdaqGS:AMPH

US$2.1b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per HUTCHMED (China)
Prezzi storici delle azioni
Prezzo attuale dell'azione	UK£3.82
Massimo di 52 settimane	UK£3.95
Minimo di 52 settimane	UK£2.05
Beta	0.65
1Variazione di 1 mese	0%
Variazione a 3 mesi	n/a
Variazione di 1 anno	5.97%
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	82.54%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	HMDC.F	US Pharmaceuticals	US Mercato
7D	0%	4.2%	2.0%
1Y	6.0%	13.7%	32.4%

Ritorno vs Industria: HMDC.F ha avuto una performance inferiore rispetto al US Pharmaceuticals che ha registrato un rendimento 13.7 % nell'ultimo anno.

Rendimento vs Mercato: HMDC.F ha avuto una performance inferiore al mercato US che ha registrato un rendimento 32.4 % nell'ultimo anno.

Volatilità dei prezzi

Is HMDC.F's price volatile compared to industry and market?
HMDC.F volatility
HMDC.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: HMDC.F non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di HMDC.F nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2000	1,990	Wei-Guo Su	www.hutch-med.com

HUTCHMED (China) Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di HUTCHMED (China) con la sua capitalizzazione di mercato?
HMDC.F statistiche fondamentali
Capitalizzazione di mercato	US$2.45b
Guadagni(TTM)	-US$29.42m
Ricavi(TTM)	US$757.24m

3.2x

Rapporto P/S

-83.3x

Rapporto P/E

HMDC.F è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
HMDC.F Conto economico (TTM)
Ricavi	US$757.24m
Costo del fatturato	US$731.89m
Profitto lordo	US$25.34m
Altre spese	US$54.77m
Guadagni	-US$29.42m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

Feb 28, 2024

Utile per azione (EPS)	-0.034
Margine lordo	3.35%
Margine di profitto netto	-3.89%
Rapporto debito/patrimonio netto	5.0%

Come si è comportato HMDC.F nel lungo periodo?

Vedi performance storica e confronto

HMDC.F Panoramica delle azioni

Premi

Analisi del rischio

HUTCHMED (China) Limited Concorrenti

NasdaqGM:WVE

US$2.3b

NasdaqGS:TARS

US$1.8b

NasdaqGM:HRMY

US$2.0b

NasdaqGS:AMPH

US$2.1b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

HUTCHMED (China) Limited Announces Appointment of Chaohong Hu as Independent Non-Executive Director and Member of Technical Committee, Effective November 21, 2024

HUTCHMED (China) Limited Announces Positive High-Level Results from the SAVANNAH Phase II Trial

Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

HUTCHMED (China) Limited Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review

Recent updates

HUTCHMED (China) Limited Announces Appointment of Chaohong Hu as Independent Non-Executive Director and Member of Technical Committee, Effective November 21, 2024

HUTCHMED (China) Limited Announces Positive High-Level Results from the SAVANNAH Phase II Trial

Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

HUTCHMED (China) Limited Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review

HUTCHMED (China) Limited to Report First Half, 2024 Results on Jul 31, 2024

Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology

HUTCHMED (China) Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED (China) Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HUTCHMED (China) Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology

HUTCHMED (China) Limited Announces Executive Changes

HUTCHMED (China) Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

HUTCHMED (China) Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

HUTCHMED (China) Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024

HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024

HUTCHMED (China) Limited Highlights Data to be Presented at AACR Congress 2024

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED (China) Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Hutchmed (China) Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session

HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

HUTCHMED (China) Limited Receives Elunate® (Fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

HUTCHMED (China) Limited Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

HUTCHMED (China) Limited Completes Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Hutchmed (China) Limited Announces First in Human, Open-Label, Dose-Escalation Study of Erk1/2 Inhibitor Hmpl-295 in Patients with Advanced Solid Tumors

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

HUTCHMED (China) Limited Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HUTCHMED (China) Limited Announces Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

Hutchmed (China) Limited Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

HUTCHMED (China) Limited Announces the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China

HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee

Hutchmed (China) Limited Initiates Phase I Study of Its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

HUTCHMED (China) Limited to Report First Half, 2023 Results on Jul 31, 2023

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

HUTCHMED (China) Limited and Takeda Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

HUTCHMED (China) Limited Announces New and Updated Clinical Data Related to HUTCHMED

HUTCHMED (China) Limited Appoints Solange Peters as Independent Non-Executive Director, Member of the Technical Committee and Member of the Audit Committee

HUTCHMED (China) Limited to Report Fiscal Year 2022 Results on Feb 28, 2023

HUTCHMED (China) Limited Announces Agreement with NHSA for Inclusion of ORPATHYS in the National Reimbursement Drug List in China

Hutchmed Completes Patient Enrollment of Eslim-01, A Phase Iii Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

HUTCHMED Initiates Rolling Submission of Nda to U.S. Fda for Fruquintinib for the Treatment of Refractory Colorectal Cancer

HUTCHMED (China) Limited Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China

Hutchmed (China) Limited Initiates Phase 2/3 Trial of Fruquintinib

HUTCHMED (China) Limited Initiates Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED (China) Limited Announces Summary Results of the 691-Patient, Multi-Regional Clinical Trial

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

HUTCHMED (China) Limited Riepilogo dei fondamenti

3.2x

-83.3x

Guadagni e ricavi